The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Abstract
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.Methods We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles. The primary endpoint was progression-free survival. Survival analysis was done with the modified intention-to-treat population. This study is registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.Findings Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel). Thus, 172 patients (86 in each group) were included in the survival analyses. The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001). Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhoea were more frequent in the gefitinib group. Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.Interpretation Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.Funding West Japan Oncology Group (WJOG): a non-profit organisation supported by unrestricted donations from several pharmaceutical companies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [30]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [145]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [5]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [8]
In the citing paper
“Most patients whose tumors harbor exon 19 deletions or L858R EGFR activating mutations have radiographic responses to monotherapy with the reversible adenosine triphosphate (ATP)-competitive EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib 17–23 and the irreversible EGFR TKI afatinib 24.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [21]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [9]
In the citing paper
“Several other trials conducted in Asia confirmed the superiority of Gefitinib over chemotherapy in EGFR-mutated patients [16, 44, 64].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [16]
In the citing paper
“Targeted therapies for these lung cancers were established based on 7 phase III randomized trials.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Randomized phase III trials have demonstrated the superiority of these TKI, in terms of progression free survival (PFS), to conventional chemotherapy in patients with lung cancers harboring EGFR mutations.5, 6, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Evidence of these common mutations has been developed in prospective trials: gefitinib, erlotinib and afatinib showed ORR of approximately 60% and PFS of 9–13 months.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [6]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [109]
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Self-citationKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,435
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 2
- Cappuzzo, 2009, Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study, J Thorac Oncol, 4
- Lee, 2009, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4
Cited by
Sorted by citations
Items 101–200 of 1,010
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, J. J., Cardarella, S., Lydon, C., Dahlberg, S. E., Jackman, D. M., Janne, P. A., & Johnson, B. E. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.103 · Cited by 358
Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 352
Yu, H. A., Sima, C. S., Huang, J. G., Solomon, S. B., Rimner, A., Paik, P. K., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 340
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Thangue, N. B. L., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 340
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W. J., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 337
Offin, M. D., Rizvi, H. A., Tenet, M., Ni, A., Sánchez-Vega, F., Li, B. T., Drilon, A. E. D. C., Kris, M. G., Rudin, C. M., Schultz, N. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 336
Sequist, L. V. D., Gettinger, S. N., Senzer, N. N., Martins, R. G., Janne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 331
Yang, J. C., Hirsh, V., Schüler, M., Yamamoto, N., O'Byrne, K. J., Mok, T. S. K., Zazulina, V., Shahidi, M., Lungershausen, J., Massey, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1764 · Cited by 330
Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1736 · Cited by 327
Self-citationKatakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., Ichinose, Y., Koboyashi, K., Takeda, K., Kiura, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0981 · Cited by 326
Self-citationBeau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324
Castellanos, E. H., Feld, E., & Horn, L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 322
Third generation EGFR TKIs: current data and future directions
Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 322
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Li, Y.-S., Jiang, B., Yang, J., Tu, H., Zhou, Q. H., Guo, W., Yan, H., & Wu, Y.-L. L. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.029 · Cited by 317
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas
Liu, Y., Kim, J., Balagurunathan, Y., Li, Q., García, A. L., Stringfield, O., Ye, Z., & Gillies, R. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.02.001 · Cited by 314
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 306
Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
D’Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 302
Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301
Wu, Y.-L. L. C., Lee, J. S., Thongprasert, S., Yu, C., Zhang, L., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Sandoval-Tan, J., Zhu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70254-7 · Cited by 302
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Lim, S. M., Syn, N. L. X., Cho, B. C., & Soo, R. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.006 · Cited by 293
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283
Suda, K., Tomizawa, K., Fujii, M., Murakami, H., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318216ee52 · Cited by 283
Self-citationAfatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Yang, J. C., Schüler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 284
Shien, K., Toyooka, S., Yamamoto, H., Soh, J., Jida, M., Thu, K. L., Hashida, S., Maki, Y., Ichihara, E., Asano, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4136 · Cited by 273
Self-citationJenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
Self-citationTsimberidou, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 268
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
Eichler, A. F., Kahle, K. T., Wang, D. L., Joshi, V. A., Willers, H., Engelman, J. A., Lynch, T. J., & Sequist, L. V. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq076 · Cited by 266
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4694 · Cited by 260
Self-citationTyrosine kinase inhibitors: Multi-targeted or single-targeted?
Broekman, F. (2010) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i2.80 · Cited by 259
Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 259
Lee, C. K., Davies, L. C., Wu, Y.-L. L. C., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw279 · Cited by 256
Self-citationMolecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · CHEST Journal · doi:10.1378/chest.12-2346 · Cited by 251
Weakly-supervised learning for lung carcinoma classification using deep learning
Kanavati, F., Toyokawa, G., Momosaki, S., Rambeau, M., Kozuma, Y., Shoji, F., Yamazaki, K., Takeo, S., Iizuka, O., & Tsuneki, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66333-x · Cited by 250
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 250
Greenhalgh, J., Dwan, K. M., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Jain, P., & Green, J. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub2 · Cited by 248
Han, W., & Lo, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.011 · Cited by 245
Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 245
Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 245
PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.122 · Cited by 246
Kazandjian, D. G., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 245
Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000504 · Cited by 241
Resisting Resistance: Targeted Therapies in Lung Cancer
Lin, J. J., & Shaw, A. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 241
Karachaliou, N., Mayo, C., Costa, C., Magrí, I., Giménez-Capitán, A. A., Molina‐Vila, M. Á., & Rosell, R. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.007 · Cited by 241
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sánchez, J. M., Porta, R., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.257 · Cited by 239
Camidge, D. R., Kono, S. A., Lu, X. J. D., Okuyama, S., Barón, A. E., Oton, A. B., Davies, A. M., Varella‐Garcia, M., Franklin, W. A., & Doebele, R. C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820cf053 · Cited by 239
Gridelli, C., Ciardiello, F., Gallo, C., Feld, R. D., Butts, C. A., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2056 · Cited by 236
Zhou, Q. H., Xu, C., Cheng, Y., Liu, Y., Chen, G., Cui, J., Yang, N., Song, Y., Li, X., Lü, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.005 · Cited by 236
Wu, S.-G., Liu, Y.-N., Tsai, M.-F., Chang, Y.-L., Yu, C.-J., Yang, P.-C., Yang, J. C.-H., Wen, Y.-F., & Shih, J.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7189 · Cited by 234
Park, K., Yu, C.-J., Kim, S.-W., Lin, M.-C., Sriuranpong, V., Tsai, C.-M., Lee, J.-S., Kang, J.-H., Chan, K. C. A., Perez-Moreno, P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4921 · Cited by 229
Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 229
Zhang, L., Ma, S., Song, X., Han, B., Cheng, Y., Huang, C., Yang, S., Liu, X., Liu, Y., Lü, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70117-1 · Cited by 228
Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823ab0dd · Cited by 226
Self-citationOu, S. I., Bartlett, C. H., Mino-Kenudson, M. A., Cui, J., & Iafrate, A. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0311 · Cited by 226
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
Yatabe, Y., Matsuo, K., & Mitsudomi, T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3906 · Cited by 223
Self-citationRecent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 222
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 224
Cancer pharmacogenomics: strategies and challenges
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3352 · Cited by 221
Gelatti, A., Drilon, A. E. D. C., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220
Lung cancer in never smokers—the East Asian experience
Zhou, F., & Zhou, C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.14 · Cited by 217
Wang, Z., Cheng, Y., An, T., Gao, H., Wang, K., Zhou, Q. H., Hu, Y., Song, Y., Ding, C., Peng, F., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30264-9 · Cited by 217
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Eschrich, S. A., Fulp, W. J., Yudi Pawitan, Y., Foekens, J. A., Smid, M., Martens, J. W. M., Echevarria, M., Kamath, V. P., Lee, J., Harris, E. E. R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0891 · Cited by 215
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 214
Hsu, P., Jablons, D. M., Yang, C., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 215
Luo, J., Shen, L., & Zheng, D. (2014) · Scientific Reports · doi:10.1038/srep06269 · Cited by 212
Okami, J., Shintani, Y., Okumura, M., Ito, H., Ohtsuka, T., Toyooka, S., Mori, T., WATANABE, S.-I. I., Date, H., Yokoi, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.002 · Cited by 212
Self-citationNaidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 211
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Zhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 207
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0440-1 · Cited by 206
Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1371 · Cited by 206
Self-citationCancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 206
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T. L., Gettinger, S. N., Hensing, T. A., Sequist, L. V. D., Ireland, B. K., & Stinchcombe, T. E. (2013) · CHEST Journal · doi:10.1378/chest.12-2361 · Cited by 206
Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000048 · Cited by 204
Niho, S., Kunitoh, H., Nokihara, H., Horai, T., Ichinose, Y., Hida, T., Yamamoto, N., Kawahara, M., Shinkai, T., Nakagawa, K., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.005 · Cited by 204
Self-citationKobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203
Self-citationNan, X., Xie, C., Yu, X., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20095 · Cited by 203
Hung, J., Jeng, W., Chou, T., Hsu, W., Wu, K., Huang, B., & Wu, Y. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828920c0 · Cited by 202
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Self-citationInfluence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer
Bai, H., Wang, Z., Chen, K., Zhao, J., Lee, J. J., Wang, S., Zhou, Q., Zhuo, M., Mao, L., An, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3744 · Cited by 199
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 200
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 198
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, É., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 195
Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw322 · Cited by 194
Self-citationGonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
Ou, S. I. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s19045 · Cited by 190
Kitamura, K., Seike, M., Okano, T., Matsuda, K., Miyanaga, A., Mizutani, H., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0448 · Cited by 190
D’Angelo, S. P., Janjigian, Y. Y., Ahye, N., Riely, G. J., Chaft, J. E., Sima, C. S., Shen, R., Zheng, J., Dycoco, J., Kris, M. G., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826bb7b2 · Cited by 184
Liao, B.-C., Lee, J., Lin, C., Chen, Y., Chang, C., Ho, C., Shih, J., Yu, C., & Yang, J. C. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000669 · Cited by 184
Metadata
- Authors
- Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., & Fukuoka, M.
- Affiliations
- Aichi Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Kindai University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Osaka City General Hospital (JP)
- Osaka Habikino Medical Center (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Kobe City Medical Center General Hospital (JP)
- Kurashiki Central Hospital (JP)
- Kouseiren Takaoka Hospital (JP)
- Osaka City University (JP)
- Tottori University (JP)
- Okayama University (JP)
- Corresponding author
- Mitsudomi, Tetsuya
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 11
- Issue
- 2
- Pages
- 121-128
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2129360604
- Cited by
- 4,090
- References
- 34
- Citations by year
- 2026: 31 · 2025: 110 · 2024: 130 · 2023: 140 · 2022: 211 · 2021: 228 · 2020: 236 · 2019: 264 · 2018: 318 · 2017: 329 · 2016: 312 · 2015: 382 · 2014: 372 · 2013: 352 · 2012: 300
- FWCI
- 187.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- gefitinib, non-small cell lung cancer, EGFR mutation, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, progression-free survival, platinum-based chemotherapy, first-line therapy, myelosuppression, postoperative recurrence
- MeSH terms
- Docetaxel, Gefitinib, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Taxoids, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
